Drug Profile
Research programme: CCR8 antagonists - Millennium Pharmaceuticals
Latest Information Update: 07 Apr 2009
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Millennium
- Class Small molecules
- Mechanism of Action CCR8 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma; Cancer; Multiple sclerosis
Most Recent Events
- 07 Apr 2009 No development reported for Allergic asthma in USA (unspecified route)
- 07 Apr 2009 No development reported for Cancer in USA (unspecified route)
- 07 Apr 2009 No development reported for Multiple sclerosis in USA (unspecified route)